Endometriosis and HRT: What to Know Before Menopause Hormone Therapy

Table of Contents

This page is educational and is not a substitute for personalized medical advice. With a history of endometriosis, HRT decisions depend on your full history; discuss your symptoms, history, and options with a licensed clinician, and ask whether a specialist review is right for you.

Can You Take HRT If You Have Endometriosis?

A history of endometriosis doesn’t automatically rule out HRT, but it makes the choice of therapy (and the decision whether to use HRT) a more individualized one that should be made together with a clinician. Hormone replacement therapy (HRT), also called menopausal hormone therapy, can help relieve symptoms of menopause like hot flashes, night sweats, and vaginal dryness, as well as protect against the bone loss that can happen during menopause.¹ It’s also considered for people going through early menopause, whether that’s natural or after surgical removal of the ovaries.

The European Society of Human Reproduction and Embryology (ESHRE) 2022 guideline suggests that combined HRT can be considered for women with a history of endometriosis, but this recommendation is based on limited evidence from relatively small studies.² There is no single answer that applies to everyone with endometriosis. The decision depends on many factors like the extent and location of the patches of endometriosis (endometriotic deposits), any treatments or surgeries performed, whether residual disease is likely, how severe menopause symptoms are, and personal factors like age and health history.

For people with endometriosis, the central question is often which type of HRT is appropriate. Endometriosis is a condition where tissue similar to the lining of the uterus (the endometrium) grows outside the uterus, commonly on the ovaries or fallopian tubes, or areas in the pelvis like the bladder and bowel.³ These deposits can respond to hormonal changes in similar ways to how the lining of the uterus does, and this is what may cause the pain, inflammation, and long-term scarring that’s associated with endometriosis.³

With endometriosis being an estrogen-dependent condition, the endometriotic tissue can respond to estrogen, so there’s a theoretical consideration around how any residual endometriotic tissue remaining after treatment or surgery would respond to estrogen-therapy.⁴ This is why the choice between estrogen-only therapy and combined therapy (where progestogen is added to protect against endometrial overgrowth) is more of a careful decision than it might be for someone without a history of endometriosis.

Why Estrogen-Only HRT Requires Caution

In people with an endometriosis history, estrogen given on its own without a progestogen (sometimes called unopposed estrogen therapy), in theory has the potential to stimulate the growth of any endometriotic tissue that remains in the body, so it requires special caution.^3,5 Some endometriotic tissue can persist after treatment for endometriosis, whether that’s medical treatment like hormonal therapy, minimally invasive surgery to remove patches of endometriosis, or in extensive cases removal of the uterus. Even if the uterus is removed, it doesn’t necessarily remove all the endometriotic tissue as it’s not solely confined to the uterus and may be present on the ovaries, elsewhere in the pelvis, or more rarely in locations outside the pelvis.

According to ESHRE, there are reports of endometriosis symptoms like pain returning after starting estrogen-only therapy, but how often this happens is not well established and the evidence base here is very limited as the findings are from only a few, low quality studies so the true risk is uncertain.³ The ESHRE recommendation was also extrapolated to women going through natural menopause, because the available studies only included women who had surgical menopause.³

There is also a rare risk of malignant transformation of residual endometriotic tissue associated with women using menopausal hormone therapy, and this is mostly found in cases of estrogen-only regimens.² Currently this is more of a theoretical risk and is based on only a few cases. However, ESHRE patient guidance advises against estrogen-only therapy for treating menopause symptoms in women with a history of endometriosis due to the possible risks of malignant transformation.² This is one of the reasons why combined therapy tends to be discussed by some clinicians for people with a history of endometriosis.

Estrogen-Only vs Combined HRT: Why the Difference Matters

The choice between estrogen-only and combined therapy is an important and very individualized decision that needs to be made between patient and clinician based on the benefits and risks of adding progestogen to the regimen.

Estrogen-Only HRT

Estrogen-only HRT is when estrogen is given without a progestogen. In the general population, this is typically used for people who no longer have a uterus, for example after a hysterectomy. Estrogen on its own can cause the lining of the uterus to thicken which can increase the risk of endometrial cancer.¹ If there is no uterus, this risk is usually less of a concern.

Combined HRT

Combined HRT means that estrogen is given together with a progestogen (either progesterone or a synthetic form called progestin). In general, combined therapy is usually used for people who still have a uterus so that the progestogen can help protect the endometrium from the effects of estrogen.

With endometriosis, this isn’t always the case and it can be a bit more complex (although the same logic still applies). Combined HRT is often discussed for people with endometriosis, even if they no longer have a uterus, because the endometriotic tissue can remain elsewhere in the pelvis even after treatment. The progestogen in combined therapy is thought to protect the residual endometriotic tissue from the effects of unopposed estrogen. This is a factor, among others, to consider when discussing treatment options with a clinician. Adding progestogen may be considered if there are some areas of endometriosis left after surgical removal or other treatment, to reduce the possibility of reactivation of residual endometriosis and the theoretical risk of malignant transformation.⁶ The location and amount of endometriotic tissue left can influence this decision.

There is, however, some uncertainty regarding the protective effect of adding a progestogen for people with endometriosis. Endometriotic tissue may show progesterone resistance, which means that it may respond less than normal endometrium to progesterone’s protective effects.⁷ A 2025 review published in the Journal of Clinical Medicine notes that this may limit the effectiveness of using progestogens in some people and could have implications for HRT choices, which is another reason that this decision needs clinician input.⁷

There is always a balance of benefits and risks, and some clinicians may prefer to prescribe estrogen-only therapy due to a possible association between combined therapy and a small increased risk of breast cancer.⁸ According to the Menopause Society, this risk is estimated to be less than one additional breast cancer case per 1,000 women per year of HRT use.⁸ The level of risk can also vary depending on the type of HRT, the regimen, how long it’s used for, previous hormone exposure, and individual characteristics.⁸ In comparison, this risk is similar to the breast cancer risk from modifiable risk factors like leading a sedentary lifestyle, obesity, or having two alcoholic drinks per day.⁸ The type of progestogen used may also be relevant. European Menopause and Andropause Society (EMAS) guidance advises that progestogen selection should be individualized according to a person’s cardiovascular risk, whether they have diabetes, and their breast cancer risk, noting that micronized progesterone and dydrogesterone have been associated with a lower cardiovascular and breast cancer risk compared with other progestogens.⁹

All of these factors are taken into consideration when deciding which HRT regimen is appropriate for each individual case.

HRT is available via several forms including oral tablets, patches, gels or sprays. While each route of delivery has its own benefits and risks profile, oral estrogen pills are associated with a higher risk of blood clots compared to other non-oral routes like estrogen patches.¹ This is a consideration for people with endometriosis as this condition is associated with an increased risk of cardiovascular disease.³ A 2025 systematic review and meta-analysis published in the European Journal of Obstetrics & Gynecology and Reproductive Biology confirmed the association between endometriosis and cardiovascular disease, and highlighted that endometriosis may increase the risk of stroke and ischemic heart disease (where the blood flow to the heart becomes restricted from narrowing or blockage of the coronary arteries).¹⁰ This may be taken into consideration by your clinician when deciding on an appropriate form of HRT, as certain forms of estrogen and progestogens are associated with higher risks of blood clots than others.

HRT After Hysterectomy for Endometriosis

Having no uterus doesn’t automatically mean estrogen-only therapy is the right choice when endometriosis is involved. For most people who have had a hysterectomy, estrogen-only therapy is generally appropriate as there is no endometrium left to protect from estrogen’s effects.¹ Endometriosis is sometimes considered an exception to this. According to the British Menopause Society surgical menopause guidance: “continued combined estrogen/progestogen HRT is advised following hysterectomy in women who have widespread endometriosis to reduce the risk of stimulation and malignant transformation of endometrial deposits”.¹¹

The European Menopause and Andropause Society takes a similar position, advising that continuous combined HRT may be safer than other forms in people with endometriosis, whether or not they’ve had a hysterectomy.⁹ This is because it may be associated with a reduced risk of recurrence and malignant transformation of any residual endometriosis compared to the risk associated with use of unopposed systemic estrogen.⁹ EMAS advises that estrogen-only therapy should be avoided even in people who have had a hysterectomy, and notes that adding a progestogen continuously is recommended despite the small increase in breast cancer risk.⁹

Current US guidance on this is limited. ACOG’s previous Practice Bulletin 114 on the management of endometriosis has been withdrawn, and its replacement Clinical Practice Guideline No.11 which was published in March 2026 addresses the diagnosis of endometriosis rather than its management.¹²^,¹³ ACOG has indicated that further guidance on management is developing.¹⁴ Currently, the guidance available on hormone therapy after definitive surgery for endometriosis comes primarily from European and UK sources. Historically, ACOG’s previous framework took a different position from current BMS guidance, stating that estrogen therapy was not contraindicated after hysterectomy and bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes) for endometriosis.¹² It also noted that although some clinicians routinely added a progestogen in this situation, there was not enough evidence to support that practice.¹²

What this means in practice is that guidance in this area is not yet settled, and clinicians may take different approaches. The extent of the surgery is relevant here. Someone who had a hysterectomy along with the removal of both ovaries as well as excision of any visible endometriotic deposits, may be in a different position to someone who had a hysterectomy alone with some endometriotic deposits left in place. It may change the likelihood of residual disease, and the reasoning behind adding a progestogen may depend on what the surgeon found during surgery and what was or wasn’t removed.

Surgical Menopause and Endometriosis

Surgical menopause (which is a type of induced menopause) happens when both of the ovaries are removed before biological menopause, which causes a sudden loss of the hormones usually produced by the ovaries, often with an abrupt onset of menopausal symptoms. Removal of the ovaries (with or without the uterus) is sometimes performed as part of treatment for endometriosis, aiming to reduce symptoms by suppressing the menstrual cycle.⁵ Endometriosis is quite often diagnosed and treated in people of reproductive age, which is below the age of natural menopause. With surgical menopause, this can have implications on long-term health as the prolonged estrogen deficiency can increase the risk of osteoporosis as well as cardiovascular disease.⁵ This is particularly relevant for people with endometriosis given the association between endometriosis and cardiovascular risk. Unlike natural menopause where estrogen levels fluctuate and then decline gradually over years, the drop in hormone levels after removal of the ovaries happens abruptly.¹¹ Apart from happening more suddenly, menopause symptoms may also be more intense than those experienced during a natural menopause transition, and it may also result in a greater severity of the potential risks seen in natural menopause including osteoporosis, cardiovascular disease, stroke, sexual dysfunction (including low libido and vaginal dryness), and cognitive changes (like mood changes, depression, and memory loss).¹¹

Guidance from the British Menopause Society states that: “all women <45 years old undergoing surgical menopause should be offered HRT at least until age 51 (average age of menopause), unless there are contraindications to treatment such as a personal history of hormone dependant cancer”.¹¹ ESHRE also recommends that combined HRT should be offered to women with a history of endometriosis after surgical menopause at minimum up until the age of natural menopause.²

The timing of starting HRT after surgery is individualized for endometriosis, and there is currently no clear consensus. Some clinicians suggest starting HRT soon after surgery to manage sudden or severe menopausal symptoms. Others may consider delaying HRT because of the theoretical possibility that residual endometriotic tissue may regress before estrogen is introduced.^5,¹⁵ This rationale is not well supported by evidence. The 2026 guidance from The British Menopause Society reflects the uncertainty, stating that there is no clear consensus on the ideal timing.⁵ Any decision should be made after a discussion between patient and clinician, weighing the theoretical concern about reactivation versus the impact of untreated menopausal symptoms.

Can HRT Reactivate Endometriosis?

HRT has the potential to stimulate residual endometriotic tissue, particularly where estrogen-alone therapy is given. ESHRE guidance notes that recurrence of symptoms has been reported, though how often this happens isn’t well established.² The evidence that HRT increases recurrence is limited, but this possibility is part of why therapy type and ongoing monitoring are important. It’s a concern that some people with an endometriosis history may want to address, especially after years of managing symptoms.

Endometriosis symptoms may recur even after removal of the uterus and both ovaries, and in some cases this appears to happen whether or not hormone therapy is used. ACOG’s withdrawn 2010 Practice Bulletin on endometriosis management cited data which indicated that endometriosis may recur in up to 15% of women after removal of both ovaries, regardless of whether estrogen therapy was used afterwards.¹²

Where recurrent symptoms are investigated surgically, endometriotic lesions may be found, and this is commonly on the bowel.¹² These endometriotic patches may have been there at the time of the original surgery and were not removed, which means they might represent persistent disease instead of recurrence.¹²

It’s also possible for endometriotic tissue to persist with low estrogen levels, including after menopause and without any hormone therapy. Endometriosis was traditionally thought to resolve after menopause because of falling estrogen levels, but it’s now recognized that this isn’t always the case. A 2021 systematic review reported that symptomatic endometriosis can affect between 2 to 4% of postmenopausal women.¹⁶

There are a few possibilities for why endometriosis can persist after menopause:

Endometriotic lesions are thought to produce estrogen locally.^7,¹⁷ The endometriotic tissue, unlike normal endometrium, also lacks a specific enzyme that breaks down estradiol (the type of estrogen made by the endometriosis tissue), which means locally produced estrogen is cleared less effectively.¹⁷
After menopause, there are still low levels of circulating estrogen, and this is mostly from something called aromatization, which is the conversion of androgens to estrone (the main type of estrogen after menopause) in fat tissue.¹⁷ This is also why obesity has been identified as a risk factor in the persistence or recurrence of postmenopausal endometriosis.
HRT is one of these several possible sources of estrogen exposure, and the impact may be greater with estrogen-alone therapy.¹⁷

Endometriotic lesions found after menopause tend to be less extensive and less active than those seen in the reproductive years.¹⁷ According to 2026 guidance from the BMS, the amount of estrogen usually given as HRT after removal of the ovaries (as part of surgical treatment for endometriosis), is theoretically considered enough to help maintain bone density and avoid menopausal symptoms, while being low enough to avoid reactivating endometriosis.⁵ The risk of reactivating endometriosis on HRT after oophorectomy is thought to be low, although there is no strong evidence for this.⁵ Measures generally discussed to mitigate this risk are using combined therapy rather than estrogen-alone therapy, and having a monitoring plan in place.⁵ In cases where recurrence does happen after starting HRT, guidelines advise referral to a specialist with an interest in menopause for further assessment and investigation.⁵

Symptoms to Report After Starting HRT

When starting HRT, having a history of endometriosis means that it’s important to report any new or returning pelvic pain or other symptoms that resemble any previous endometriosis symptoms to a clinician. The purpose of monitoring is to make sure that if anything does change, it’s picked up and reviewed early.

Symptoms that are worth reporting include:^7,3

Pelvic pain, especially if it feels similar to any pain experienced previously with endometriosis
Pain during or after sex
Urinary symptoms like pain when passing urine
Bowel symptoms like pain when emptying the bowel or a change in bowel habits
Any unexplained vaginal bleeding
A pelvic mass or abdominal swelling
Pain or bleeding in other areas like the urinary tract or rectum

Symptoms of endometriosis in the postmenopausal years can be less specific than they were during the reproductive years, partly because there’s no longer a menstrual cycle to relate them to and the symptoms aren’t typically ‘cyclical’.⁷ The bowel and urinary symptoms in particular can be mistaken for other conditions, which is one of the reasons why mentioning these symptoms to your clinician is worthwhile.

There are certain symptoms (such as breast tenderness, bloating, headaches, or breakthrough bleeding) that are quite common general side effects in the first few months of starting HRT, and these usually settle.¹ Any unexplained vaginal bleeding however should always be reported promptly, whether or not you have an endometriosis history, as it needs to be assessed. If there is any uncertainty surrounding what could be a general HRT side effect or whether it’s related to endometriosis, it’s advisable to raise this with a clinician.

Questions to Ask an HRT Provider If You Have Endometriosis

If you have endometriosis, it may be helpful to be aware of some questions which could be helpful as part of a conversation you have with a clinician when discussing HRT.

Questions about the type of therapy:

Considering my endometriosis history, would you recommend estrogen-only or combined therapy, and what’s your reasoning? What are the benefits and risks of each?
Even if I’ve had a hysterectomy, would combined therapy still be recommended in my case?
Which form of HRT would you suggest for me, and why?
Would transdermal estrogen (patch, gel, or spray) be a better option than tablets in my case?

Questions about my history:

What information do you need from me regarding my previous surgery or treatment for endometriosis?
Does the fact that I’ve had my uterus and/or both ovaries removed affect my HRT plan?
Does the extent of my previous surgery affect what HRT options are appropriate for me now and is there any concern that residual endometriosis could still respond to estrogen?
Would it help if I requested my operating surgeon’s notes or my hospital records?

Questions about monitoring:

How will we monitor for any returning endometriosis symptoms?
How often will you want to review my treatment?
What symptoms should prompt me to contact you sooner?
Are there any warning signs that would need urgent investigation?

Questions about long-term health:

How important is HRT for things like bone and cardiovascular health if I experience early or surgical menopause?
What are the risks of taking HRT with regards to blood clots, heart disease, endometrial cancer and breast cancer, and how does this change with my history of endometriosis?

Questions about alternative options:

If HRT isn’t suitable for me, are there other treatment options available for my menopausal symptoms?
If my symptoms return whilst on HRT, would we adjust the dose or type, or stop HRT altogether?
Are there any lifestyle changes that could help alongside HRT?

Questions about specialist involvement:

Do you think my history warrants review by a gynecologist or menopause specialist?
Are you comfortable managing HRT in someone with my history, or would you prefer to refer me?

It can be helpful to bring a record of your endometriosis history to your appointment, including when you were diagnosed, what treatments you’ve had, what surgery you’ve had (including what was found and removed).

When to See an OB-GYN or Menopause Specialist

Some people with a history of endometriosis may benefit from review by an OB-GYN or menopause specialist, especially if they have a complex medical or surgical history, are in surgical menopause, develop returning pelvic pain, or have unexplained bleeding. While many people can have their menopause managed by their usual clinician, endometriosis can make the clinical picture and HRT decisions more complex, especially when considering previous surgery, the likelihood of residual disease, and the most appropriate HRT regimen.

The British Menopause Society advises that HRT decisions after surgical menopause should be made on a case-by-case basis, taking into account factors like the extent of residual disease and the balance between the benefits of HRT and the potential risk of endometriosis recurrence. BMS also recommends referral to a specialist with an interest in menopause if symptoms persist.⁵

Situations where a referral to an OB-GYN or menopause specialist may be appropriate:

A history of extensive or deep endometriosis
Surgical menopause after removal of both ovaries
Uncertainty whether estrogen-only or combined HRT is the most appropriate option
New or returning pelvic pain after starting HRT
Unexplained vaginal bleeding
Ongoing symptoms despite treatment

FAQs

Yes, it is possible to continue HRT after the natural age of menopause if you have a history of endometriosis, but the decision becomes more individualized past that point. Guidance generally recommends that systemic HRT is offered at least until the average age of natural menopause (51 years) for people who experience early or surgical menopause.¹¹ This is largely to protect bone and cardiovascular health during the years when estrogen would normally still be present, as well as to avoid sudden or severe menopausal symptoms.¹¹ After the natural age of menopause, continuing HRT is a decision to be made together with your clinician based on any ongoing symptoms and the balance of benefits and risks of continuing HRT.

Yes, several non-hormonal options are available if you would prefer to avoid hormone therapy or if it’s not appropriate for you. However, these options are generally less effective for treating vasomotor symptoms compared to HRT.^18,9 For hot flashes and night sweats, fezolinetant (Veozah) is FDA-approved and works through a non-hormonal mechanism where it targets temperature regulation pathways within the brain.^19,20 Fezolinetant carries an FDA Boxed Warning for rare but serious liver injury, which was added in December 2024.¹⁹ Liver function testing is required before starting treatment, then monthly for the first three months, and again at months six and nine.¹⁹ Elinzanetant (Lynkuet) is a newer medication (FDA approved in 2025) which works in a similar way to fezolinetant and appears to be better tolerated.²¹ Low-dose paroxetine (Brisdelle) is an FDA-approved antidepressant approved for treatment of hot flashes, while gabapentin (an anti-convulsant) may in some cases be used off-label to treat vasomotor symptoms.²² Cognitive behavioral therapy may help with the emotional impact of dealing with chronic pelvic pain and menopausal symptoms. For bone protection, medications like bisphosphonates along with calcium and vitamin D may be considered. EMAS guidance advises avoiding herbal and botanical preparations as their effectiveness is uncertain and they may have some estrogenic compounds, which is a particular consideration if you have endometriosis.⁹

There is no evidence that compounded bioidentical hormones are safer or more effective than FDA-approved HRT, and this applies to endometriosis as much as to menopause in general. The FDA does not regulate compounded products for dose accuracy and quality like it does for approved medications.¹ FDA-approved bioidentical hormones exist (including estradiol and micronized progesterone), and the American College of Obstetricians and Gynecologists advises to use these as first-line option where possible.²³

Vaginal estrogen is generally considered suitable as an option to treat symptoms of genitourinary syndrome of menopause (GSM) like vaginal dryness, irritation, or discomfort during sex. According to EMAS, vaginal lubricants and moisturizers are first-line for GSM, and vaginal estrogen is one of the second-line treatments for GSM.⁹ Only a small amount is absorbed into the bloodstream, and according to EMAS, vaginal estrogen does not appear to significantly increase the risk of endometrial hyperplasia or cancer.⁹ However, it is recommended that vaginal estrogens are inserted into the lower third of the vagina to avoid the venous connection between the upper vagina and the uterus and ovaries, to minimize the risk of hormone being carried through that blood supply.⁹

References

American College of Obstetricians and Gynecologists. Hormone therapy for menopause [Internet]. Washington, DC: ACOG; 2024. Available from: https://www.acog.org/womens-health/faqs/hormone-therapy-for-menopause
Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE Endometriosis Guideline Group, ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009. Available from: https://academic.oup.com/hropen/article/2022/2/hoac009/6537540.
ESHRE Endometriosis Guideline Development Group. Endometriosis: Guideline of European Society of Human Reproduction and Embryology [Internet]. Available from: https://www.eshre.eu/-/media/sitecore-files/Guidelines/Endometriosis/ESHRE-GUIDELINE-ENDOMETRIOSIS-2022_1.pdf
Vannuccini S, Clemenza S, Rossi M, Petraglia F. Hormonal treatments for endometriosis: The endocrine background. Rev Endocr Metab Disord. 2022 Jun;23(3):333-355. doi: 10.1007/s11154-021-09666-w. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9156507/
British Menopause Society. BMS Tool for clinicians: induced menopause in women with endometriosis [Internet]. Feb 2026. Available from: https://thebms.org.uk/wp-content/uploads/2026/02/10-NEW-BMS-TfC-Induced-Menopause-in-women-with-endometriosis-FEB2026-B.pdf
Piriyev E, Schiermeier S, Römer T. Hormonal Treatment of Endometriosis: A Narrative Review. Pharmaceuticals (Basel). 2025 Apr 17;18(4):588. doi: 10.3390/ph18040588. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11576634/
Raheem M, Condous G, Espada Vaquero M. Endometriosis During Peri-Menopause and Post-Menopause: A Review of the Literature. J Clin Med. 2025 Nov 14;14(22):8067. doi: 10.3390/jcm14228067. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12653351/
The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767–94. Available from: https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
Erel CT, Nigdelis MP, Erkan IBO, Goulis DG, Chedraui P, et al. Endometriosis and menopausal health: An EMAS clinical guide, Maturitas, Volume 202, 2025, 108715, ISSN 0378-5122, Available from: https://doi.org/10.1016/j.maturitas.2025.108715.
Saad M, Ansari I, Ibrahim ZS, Arshad MS, Collins P, et al. Increased risk of cardiovascular disease in women with endometriosis: A systematic review and meta-analysis
European Journal of Obstetrics and Gynecology and Reproductive Biology, 2025; 312. Available from: https://www.ejog.org/article/S0301-2115(25)00357-4/fulltext
British Menopause Society. BMS Tool for clinicians: Surgical menopause: a toolkit for healthcare professionals. [Internet]. Sep 2024. Available from: https://thebms.org.uk/wp-content/uploads/2024/10/13-BMS-TfC-Surgical-Menopause-SEPT2024-D.pdf
[Withdrawn] Practice Bulletin No. 114: Management of Endometriosis (2010). Obstetrics & Gynecology, 116(1), 223–236. https://doi.org/10.1097/AOG.0b013e3181e8b073
Diagnosis of Endometriosis: ACOG Clinical Practice Guideline No. 11 (2026). Obstetrics & Gynecology, 147(3), 432–448. https://doi.org/10.1097/AOG.0000000000006181
American College of Obstetricians and Gynecologists. ACOG publishes new endometriosis clinical guidance aiming to shorten time to diagnosis and improve access to care [press release]. Feb 2026. Available from: https://www.acog.org/news/news-releases/2026/02/acog-publishes-new-endometriosis-clinical-guidance-aiming-shorten-time-diagnosis-improve-access-care
Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, et al. The management of menopause in women with a history of endometriosis: a systematic review. Hum Reprod Update. 2017 Jul 1;23(4):481-500. doi: 10.1093/humupd/dmx011. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5850813/
Giannella L, Marconi C, Di Giuseppe J, Delli Carpini G, Fichera M, et al. Malignant Transformation of Postmenopausal Endometriosis: A Systematic Review of the Literature. Cancers 2021, 13, 4026. Available from: https://www.mdpi.com/2072-6694/13/16/4026
Cassani C, Tedeschi S, Cucinella L, Morteo V, Camnasio CA, et al. Menopause and endometriosis, Maturitas, Volume 190, 2024, 108129, ISSN 0378-5122. Available from: https://www.sciencedirect.com/science/article/pii/S037851222400224X
Madsen TE, Sobel T, Negash S, Shrout Allen T, Stefanick ML, et al. Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause. Int J Womens Health. 2023 May 25;15:825-836. doi: 10.2147/IJWH.S379808. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10226543/
U.S. Food and Drug Administration. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause.. [Internet]. Silver Spring: FDA; 2026. Available from: https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
Pogoda K, Arecco L, Lambertini M. Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant, The Breast, Volume 88, 2026, 104812, ISSN 0960-9776. Available from: https://www.sciencedirect.com/science/article/pii/S0960977626001220
U.S. Food and Drug Administration. LYNKUET (elinzanetant) tablets, for oral use: Prescribing information. October 2025. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219469s000lbl.pdf
The 2023 nonhormone therapy position statement of the North American Menopause Society. Menopause. 2023;30(6):573-590. Available from: https://menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf
American College of Obstetricians and Gynecologists. Compounded bioidentical menopausal hormone therapy. Clinical Consensus No. 6. [Internet] Washington DC: ACOG; 2023;142(6):1358–66. Available from: https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapy